A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus

F1000Research

Volumn 3, Issue , 2014, Pages

  Ekins, Sean ^a,b   Freundlich, Joel S ^c   Coffee, Megan ^d  

^a Collaborations in Chemistry ^*  (United States)

^b Collaborative Drug Discovery ^*  (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; CHLOROQUINE; CLOMIFENE; TOREMIFENE; UNCLASSIFIED DRUG; VIRAL PROTEIN 35; VIRUS PROTEIN;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; EBOLA VIRUS; FOOD AND DRUG ADMINISTRATION; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; NONHUMAN; PHARMACOPHORE; PROTEIN INTERACTION; PROTEIN STRUCTURE; VIRUS STRAIN;

EID: 84923345145     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.5741.2     Document Type: Article

References (35)

1. Butler D Morello L: Ebola by the numbers: The size, spread and cost of an outbreak. Nature. 2014;514(7522):284-5. 25318501 10.1038/514284a
2. Piot P: Ebola's perfect storm. Science. 2014;345(6202):1221. 25214580 10.1126/science.1260695
3. Trad MA Fisher DA Tambyah PA: Ebola in west Africa. Lancet Infect Dis. 2014;14(11):1045. 25218096 10.1016/S1473-3099(14)70924-7
4. Dhillon RS Srikrishna D Sachs J: Controlling Ebola: next steps. Lancet. 2014;384(9952):1409-1411. 25308287 10.1016/S0140-6736(14)61696-2
5. Anon: Call to action. Nature. 2014;514(7524):535-536. 25355322 10.1038/514535b
6. Check Hayden E: The Ebola questions. Nature. 2014;514(7524):554-7. 25355344 10.1038/514554a
7. Piot P: The F1000Research: Ebola article collection. F1000Res. 2014;3:269. 10.12688/f1000research.5685.1
8. Madrid PB Chopra S Manger ID: A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013;8(4):e60579. 23577127 10.1371/journal.pone.0060579 3618516
9. Johansen LM Brannan JM Delos SE: FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013;5(190):190ra79. 23785035 10.1126/scitranslmed.3005471 3955358
10. Keyaerts E Li S Vijgen L: Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416-21. 19506054 10.1128/AAC.01509-08 2715625
11. Boonyasuppayakorn S Reichert ED Manzano M: Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res. 2014;106:125-34. 24680954 10.1016/j.antiviral.2014.03.014
12. Acosta EG Bruttomesso AC Bisceglia JA: Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro. Virus Res. 2008;135(2):203-12. 18462821 10.1016/j.virusres.2008.03.014
13. Dyall J Coleman CM Hart BJ: Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885-93. 24841273 10.1128/AAC.03036-14 4136000
14. Han Z Lu J Liu Y: Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J Virol. 2014;88(13):7294-306. 24741084 10.1128/JVI.00591-14 4054416
15. Brown CS Lee MS Leung DW: In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol. 2014;426(10):2045-58. 24495995 10.1016/j.jmb.2014.01.010 4163021
16. Chakraborty S Rao B Asgeirsson B: Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions [v1; ref status: approved with reservations 1, http://f1000r.es/4lg]. F1000Res. 2014;3:251. 10.12688/f1000research.5573.1
17. Lamichhane G Freundlich JS Ekins S: Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio. 2011;2(1):e00301-10. 21285434 10.1128/mBio.00301-10 3031304
18. Ekins S Bradford J Dole K: A collaborative database and computational models for tuberculosis drug discovery. Mol Biosyst. 2010;6(5):840-851. 20567770 10.1039/b917766c
19. Zheng X Ekins S Raufman JP: Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm. 2009;6(5):1591-1603. 19673539 10.1021/mp900163d 2757534
20. Meslamani J Li J Sutter J: Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling. J Chem Inf Model. 2012;52(4):943-55. 22480372 10.1021/ci300083r
21. Rao SN Head MS Kulkarni A: Validation studies of the site-directed docking program LibDock. J Chem Inf Model. 2007;47(6):2159-71. 17985863 10.1021/ci6004299
22. Diao L Ekins S Polli JE: Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res. 2009;26(8):1890-1900. 19437106 10.1007/s11095-009-9905-3 2891772
23. Zheng X Ekins S Raufman JP: Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm. 2009;6(5):1591-603. 19673539 10.1021/mp900163d 2757534
24. Diao L Ekins S Polli JE: Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm. 2010;7(6):2120-2131. 20831193 10.1021/mp100226q 2997942
25. Ekins S Diao L Polli JE: A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. Mol Pharm. 2012;9(4):905-913. 22339151 10.1021/mp200438v 3319199
26. Dong Z Ekins S Polli JE: Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm. 2013;10(3):1008-19. 23339484 10.1021/mp300453k 3617406
27. Dong Z Ekins S Polli JE: Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. Eur J Pharm Sci. 2014;66C:1-9. 25220493 10.1016/j.ejps.2014.09.005
28. Kazmi F Hensley T Pope C: Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41(4):897-905. 23378628 10.1124/dmd.112.050054 3608459
29. Nadanaciva S Lu S Gebhard DF: A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro. 2011;25(3):715-23. 21184822 10.1016/j.tiv.2010.12.010
30. de Wilde AH Jochmans D Posthuma CC: Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875-84. 24841269 10.1128/AAC.03011-14 4136071
31. Vincent MJ Bergeron E Benjannet S: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. 16115318 10.1186/1743-422X-2-69 1232869
32. Ekins S Freundlich JS: Computational models for tuberculosis drug discovery. Methods Mol Biol. 2013;993:245-62. 23568475 10.1007/978-1-62703-342-8_16
33. Ekins S Freundlich JS Choi I: Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. Trends Microbiol. 2011;19(2):65-74. 21129975 10.1016/j.tim.2010.10.005 3034835
34. Ekins S Williams AJ Krasowski MD: In silico repositioning of approved drugs for rare and neglected diseases. Drug Disc Today. 2011;16(7-8):298-310. 21376136 10.1016/j.drudis.2011.02.016
35. Ekins S Freundlich JS Coffee M: Dataset 1 in: A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000Research. 2014. Data Source